V 85546

Drug Profile

V 85546

Alternative Names: AS-111793; MMP-12 inhibitor - Merck Serono; V85546

Latest Information Update: 16 Mar 2016

Price : $50

At a glance

  • Originator Merck Serono; Vernalis
  • Developer Vernalis
  • Class Anti-inflammatories
  • Mechanism of Action Matrix metalloproteinase 12 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes - Inflammation

Highest Development Phases

  • Suspended Inflammation

Most Recent Events

  • 16 Mar 2016 V 85546 is still available for licensing (http://vernalis.com)
  • 12 Nov 2010 V 85546 is available for licensing for inflammatory disorders in World as of 22 Oct 2008. http://www.vernalis.com/
  • 22 Oct 2008 Phase-I clinical trials in Inflammation in Europe (unspecified)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top